{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"47"},{"groupId":"BG003","value":"59"}],"units":"Participants"}],"groups":[{"description":"Rituximab, methotrexate, temozolomide 100 mg/m\\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\\^2.","id":"BG000","title":"Phase I: Temozolomide 100 mg"},{"description":"Rituximab, methotrexate, temozolomide 150 mg/m\\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\\^2.","id":"BG001","title":"Phase I: Temozolomide 150 mg"},{"description":"Rituximab, methotrexate, temozolomide 100 mg/m\\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\\^2.","id":"BG002","title":"Phase II: Temozolomide 100 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"43","upperLimit":"70","value":"57"},{"groupId":"BG001","lowerLimit":"47","upperLimit":"72","value":"62"},{"groupId":"BG002","lowerLimit":"24","upperLimit":"73","value":"57"},{"groupId":"BG003","lowerLimit":"24","upperLimit":"73","value":"57"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"30"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"29"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligible patients who started study treatment"}